by Jeff Hansen, University of Alabama at Birmingham Credit: Pixabay/CC0 Public Domain Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the monoclonal antibody dupilumab, according to a yearlong, Phase 3 clinical trial reported in the New England Journal of Medicine. These improvements—as measured by a significantly lower...
